Medical Tourism and Cross-Border Care: What Insurers and Employers Need to Know

Medical tourism — the practice of travelling to another country specifically to receive planned medical treatment — has grown from a curiosity into a mainstream feature of global healthcare. The Medical Tourism Association estimates that between 14 and 16 million people cross international borders each year for planned treatment, generating a market worth well over USD 100 billion annually. That number is rising.

For international health insurers, third-party administrators, and the employers who fund group health plans, medical tourism is no longer an edge case to be handled ad hoc. It is a structural feature of the risk pool that demands deliberate policy, robust operational processes, and a clear position on what the plan will and will not cover.

This article examines why patients seek cross-border care, how international health plans should approach it, and what a well-run TPA does to manage the complexity — from preauthorisation through to post-treatment follow-up.

The motivations behind medical tourism are more varied than popular coverage suggests. Cost is one factor, but it is rarely the only one.

The most widely cited driver is price. A hip replacement that costs USD 40,000 in the United States might cost USD 12,000 in Thailand, USD 9,000 in India, or USD 15,000 in Germany — with comparable or superior clinical outcomes. For self-funded employers and individuals with high deductibles, the arithmetic is compelling.

Cost differentials are not uniform across procedures. They are most pronounced in elective orthopaedic surgery, dental and orthodontic work, bariatric procedures, fertility treatment, and cosmetic surgery. They are less significant for emergency care, where geography is determined by circumstance rather than choice.

Some patients travel not to save money but to access a specific surgeon, a particular technology, or a centre of excellence that does not exist in their home country. Proton beam therapy, certain robotic surgical platforms, and highly specialised oncology protocols are concentrated in a small number of facilities globally. A patient in West Africa seeking treatment for a rare cancer may have no viable option other than travelling to Europe or North America.

In countries with public healthcare systems, waiting times for elective procedures can stretch to months or years. A patient in the United Kingdom waiting eighteen months for a knee replacement may choose to travel to a private facility in Poland or Hungary where the same procedure can be performed within weeks.

For certain procedures — particularly those carrying social stigma in the patient's home country, such as fertility treatment, gender-affirming surgery, or addiction treatment — travelling abroad offers a degree of privacy that local treatment cannot.

Medical tourism creates a genuine policy challenge for international health plans. The core tension is between member autonomy and plan integrity.

Most international private medical insurance (IPMI) plans are designed to cover treatment wherever it is medically necessary, subject to preauthorisation for planned procedures. In principle, this means a member can seek treatment in any country where the plan has network access or where direct billing can be arranged.

In practice, plans vary considerably in how they handle cross-border treatment:

Open network plans allow members to seek treatment at any licensed facility globally, subject to preauthorisation. The plan pays the provider directly or reimburses the member. This model maximises flexibility but creates significant administrative complexity and cost uncertainty.

Preferred provider network plans direct members to a curated network of vetted facilities. Treatment outside the network may be covered at a reduced rate or require additional justification. This model gives the insurer greater cost control and quality assurance but limits member choice.

Destination-specific exclusions are used by some plans to exclude treatment in countries where quality standards are uncertain or where the plan has no established provider relationships. These exclusions are increasingly difficult to justify as accreditation standards have improved globally.

The most significant concern for any plan covering cross-border treatment is clinical quality. Not all hospitals are equal, and the consequences of a poorly performed procedure in a foreign country — where the patient has no established relationship with the healthcare system and may face language barriers — can be severe.

The international accreditation landscape has improved substantially. Joint Commission International (JCI) accreditation is now held by over 1,000 hospitals in more than 70 countries. ISO 9001 certification, ACHS International accreditation, and various national quality frameworks provide additional benchmarks. A well-run TPA maintains a database of accredited facilities and uses accreditation status as a primary filter when recommending providers for cross-border treatment.

Accreditation is necessary but not sufficient. Procedure-specific outcomes data, surgeon credentials, volume benchmarks (the relationship between procedure volume and outcomes is well established in surgical literature), and infection rates all contribute to a meaningful quality assessment. The best TPAs go beyond accreditation to maintain proprietary quality scorecards for the facilities in their network.

One of the most underappreciated risks in medical tourism is the continuity of care problem. A patient who undergoes a complex procedure abroad and then returns home faces a transition between two healthcare systems that may have different records formats, different clinical protocols, and no established relationship. If complications arise — and in complex surgery, complications are not rare — the receiving clinician may have incomplete information about what was done, what implants were used, and what the post-operative plan was.

A responsible plan and TPA address this proactively. Pre-travel briefings, standardised medical records in the patient's language, direct communication channels between the treating facility and the home-country follow-up clinician, and clear escalation protocols for post-operative complications are all elements of a well-managed cross-border treatment programme.

A medical TPA adds value at every stage of the cross-border treatment journey.

When a member requests preauthorisation for planned treatment abroad, the TPA's clinical team should conduct a structured case assessment. This involves reviewing the clinical indication, confirming that the proposed treatment is appropriate for the diagnosis, assessing whether the proposed facility meets quality standards, and — where relevant — exploring whether equivalent treatment is available closer to the member's home country at lower cost or risk.

The preauthorisation process should also include a financial assessment. The TPA should obtain a detailed cost estimate from the proposed facility, confirm what is included (surgeon fees, anaesthesia, implants, post-operative care, physiotherapy), and identify any items that may generate additional charges. Surprise billing is a significant source of member dissatisfaction and plan leakage in cross-border treatment.

For complex procedures, active case management during the treatment episode is essential. This means maintaining contact with the treating facility, monitoring the patient's progress, and being positioned to intervene if complications arise or if the treatment plan changes materially from what was preauthorised.

The TPA should also manage the financial relationship with the provider during this phase. Direct billing arrangements — where the TPA pays the facility directly rather than requiring the member to pay and seek reimbursement — reduce financial stress on the member and give the TPA greater visibility into costs as they accrue.

When the acute treatment episode is complete, the TPA's role shifts to ensuring safe repatriation and continuity of care. For straightforward procedures, this may simply mean confirming that the member is fit to travel and providing documentation for the home-country clinician. For complex cases — major surgery, oncology treatment, cardiac procedures — it may involve arranging medical escort, coordinating with the receiving hospital, and establishing a follow-up care plan.

The TPA should also conduct a post-treatment review of the case. Were costs within the preauthorised range? Were there any quality concerns? Were there any gaps in the care pathway that should be addressed for future cases? This feedback loop is essential for continuous improvement of the cross-border treatment programme.

Medical tourism is often assumed to be inherently cost-effective, but this is not always true. The headline procedure cost may be lower, but the total cost of a cross-border treatment episode — including travel, accommodation, companion costs, and the cost of managing any complications — can erode or eliminate the apparent saving.

A rigorous cost-benefit analysis should be conducted for any significant cross-border treatment. The TPA should model the full episode cost, not just the procedure fee, and compare it against the cost of equivalent treatment in the member's home country or in a lower-cost regional alternative.

Where cross-border treatment does offer genuine cost savings, the plan and employer should consider how to share those savings with the member in a way that incentivises appropriate behaviour. Some self-funded employer plans offer members a cash incentive — a share of the saving — for choosing a lower-cost destination. This aligns member and plan interests and can generate significant aggregate savings across a large population.

Cross-border treatment creates regulatory complexity that plans and TPAs must navigate carefully.

Data protection: Patient health data transferred across borders is subject to the data protection laws of both the sending and receiving jurisdiction. GDPR applies to data transfers from the European Economic Area. Many other jurisdictions have their own data localisation requirements. The TPA must ensure that its data handling practices comply with all applicable regulations.

Liability: If a cross-border treatment results in a poor outcome, questions of liability are complex. The treating facility is subject to the laws of the country where it operates. The insurer and TPA may face claims in the member's home country. Clear contractual frameworks with treating facilities, and appropriate professional indemnity cover, are essential.

Regulatory approval: Some treatments require regulatory approval in the member's home country before they can be performed abroad and the results recognised. Fertility treatment, in particular, is subject to varying regulatory frameworks across jurisdictions.

For employers and insurers who want to take a proactive approach to cross-border treatment — rather than simply responding to individual member requests — a structured programme offers significant advantages.

A well-designed programme identifies the procedures where cross-border treatment offers the best combination of cost saving, quality assurance, and member experience. It establishes preferred provider relationships with accredited facilities in key destinations. It creates a streamlined preauthorisation and case management process. And it communicates clearly to members what the programme offers, how to access it, and what support they will receive throughout the treatment journey.

Globalwide Mediassist works with employers and insurers to design and operate cross-border treatment programmes that deliver measurable cost savings without compromising on clinical quality or member experience. Our provider network spans over 190 countries, and our clinical team has experience managing complex cross-border cases across every major medical specialty.

Medical tourism is a permanent feature of the international healthcare landscape. For international health plans and the employers who fund them, the question is not whether to engage with it but how to do so in a way that protects members, controls costs, and maintains the integrity of the plan.

The answer lies in deliberate policy, rigorous quality assurance, active case management, and a TPA partner with the network, the clinical expertise, and the operational capability to manage cross-border treatment at scale. Done well, cross-border care is not a risk to be managed — it is an opportunity to deliver better outcomes at lower cost for members and plan sponsors alike.